ALGRX 1207

Drug Profile

ALGRX 1207

Alternative Names: 1207; ALGRX-1207

Latest Information Update: 22 Jan 2007

Price : $50

At a glance

  • Originator Anesiva
  • Class Anaesthetics; Analgesics
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anaesthesia; Neuropathic pain

Most Recent Events

  • 18 Jan 2007 Discontinued - Preclinical for Anaesthesia in USA (Topical)
  • 18 Jan 2007 Discontinued - Preclinical for Neuropathic pain in USA (Topical)
  • 18 Jan 2007 Discontinued - Phase-I for Anaesthesia in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top